Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use
V B Kraus, F J Blanco, M Englund, M A Karsdal, L S Lohmander, V B Kraus, F J Blanco, M Englund, M A Karsdal, L S Lohmander
Abstract
Osteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulate use of standardized nomenclature for OA that could serve as building blocks for describing OA and defining OA phenotypes, in short to provide unifying disease concepts for a heterogeneous disorder; and (2) To stimulate establishment of ROAD (Risk of OA Development) and ROAP (Risk of OA Progression) tools analogous to the FRAX™ instrument for predicting risk of fracture in osteoporosis; and (3) To stimulate formulation of tools for identifying disease in its early preradiographic and/or molecular stages - REDI (Reliable Early Disease Identification). Consensus around more sensitive and specific diagnostic criteria for OA could spur development of disease modifying therapies for this entity that has proved so recalcitrant to date. We fully acknowledge that as we move forward, we expect to develop more sophisticated definitions, terminology and tools.
Keywords: Anatomy; Biomarkers; Criteria; Definition; Osteoarthritis; Physiology.
Conflict of interest statement
Conflicts of Interest
Virginia Byers Kraus -- Has received salary support through NIH grants PO1 AR050245 and AG028716; lecture/consultancy fees from Merrimack Pharmaceuticals, Flexion Therapeutics, Bioiberica and Abbott. She is an Associate Editor of Osteoarthritis & Cartilage.
Francisco J Blanco -- has received Grants (Clinical Trials, conferences, advisor and publications) from: Abbvie, Amgen, Bioiberica, Bristol Mayer, Celgene, Celltrion, Cellerix, Grunenthal, Gebro Pharma, Lilly, MSD, Merck Serono, Pfizer, Pierre-Fabra, Roche, Sanofi, Servier and UCB.
Martin Englund – has received honorarium for lectures in a course in clinical epidemiology from Pfizer and for a lecture in knee OA from Össur.
Morten Karsdal - is a full time employee of Nordic Bioscience, a company engaged in biomarker and medicinal product research and development.
Stefan Lohmander -- Relevant financial activities outside the submitted work include consultancy for Abbvie, Flexion, Galapagos, Medivir, MerckSerono, Teijin, Össur. Employment as Editor-in-Chief of Osteoarthritis and Cartilage.
Copyright © 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Figures
Source: PubMed